Sanofi announced today the immediate adoption of influenza strains selected by the US Food and Drug Administration (FDA) to advance the manufacturing and delivery of its vaccine portfolio for the 2025 ...

Sanofi adopts US FDA-selected flu strains to ensure readiness for the 2025-26 flu season: Bridgewater, New Jersey Monday, March 17, 2025, 14:00 Hrs [IST] Sanofi announced the imme ...

Sanofi (SNY) announced the immediate adoption of influenza strains selected by the Food and Drug Administration to advance the manufacturing ...

Sanofi stock is surging with a Golden Cross formation and promising Dupixent results. With FDA review and potential approval, investors are excited.

Latigo Biotherapeutics has whipped together a $150 million series B fundraising round to advance a pipeline of non-opioid ...

Attorney General Aaron M. Frey announced a settlement agreement with Sanofi-Aventis U.S. LLC after scrutiny over the ...

Amicus Therapeutics benefits from strong revenue and limited competition. Learn why FOLD stock is a BUY, with a favorable ...

Amezosvatein has shown excellent immunogenicity and improved tolerability in Phase 2 study -- Medicxi leads round, joined by new investors ...

In its effort to rival GSK’s shingles vaccine Shingrix, Curevo Vaccine has circled up $110 million and recruited two former ...

Sanofi has said it plans to start discussions about filing its oral BTK inhibitor tolebrutinib for multiple sclerosis, even though the drug only achieved its primary objective in one of three ...

Adults taking the novel once-daily oral pill for plaque psoriasis have significantly higher rates of clear or almost clear ...

Sanofi is tapping San Francisco-based Atomwise for a new AI-fuelled drug discovery deal, paying $20 million for five new drug targets — and possibly spending more than a billion in milestone ...